Clinical Trial Update: Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term deferiprone treatment in Pantothenate Kinase-Associated Neurodegeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pantothenate Kinase-associated Neurodegeneration

Drugs mentioned

• Deferiprone (deferiprone)

Snippet

Sponsor: ApoPharma | Conditions: Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Status: COMPLETED | Results posted: 2019-07-17